Physician profile
Daniel Greenberg
NPI 1053872143
$7,397.25
in general payments reported to CMS, 2019-2025
14 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $2,079 · 2024: $3,663 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,238 · Travel and Lodging: $1,712 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.21 |
| Travel and Lodging | $1,711.81 |
| Education | $322.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $2,426.97 | 2024-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $1,466.17 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $969.18 | 2023-2025 | |
| Astellas Pharma US INC | $667.61 | 2023-2025 | Cresemba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.33 | 2022-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $451.86 | 2024-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $367.60 | 2023-2025 | Dupixent |
| Shionogi INC | $241.63 | 2023-2025 | Fetroja |
| Actelion Pharmaceuticals US, INC. | $123.21 | 2024 | Uptravi, Opsumit |
| Verona Pharma, INC. | $28.38 | 2025 | Ohtuvayre |
| Insmed, INC. | $19.42 | 2025 | Brinsupri, Arikayce |
| Janssen Pharmaceuticals, INC | $17.19 | 2024 | Xarelto |
| Electromed, INC. | $15.70 | 2025 | Smartvest |
| Grifols Shared Services North America, INC. | $5.00 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.